60979-25-1

Basic information

• Product Name: 3-amino-4-methoxybenzonitrile
• Synonyms: 3-amino-4-methoxybenzonitrile;5-Cyano-2-methoxyaniline, 2-Amino-4-cyanoanisole;5-Cyano-2-Methoxy-aniline;Benzonitrile, 3-aMino-4-Methoxy-
• CAS NO: 60979-25-1
• Molecular Formula: C₈H₈N₂O
• Molecular Weight: 148.16192
• Mol File: 60979-25-1.mol
• Article Data: 12

Chemical Properties

• Melting Point: 84 °C
• Boiling Point: 332.8 °C at 760 mmHg
• Flash Point: 155.1 °C
• Appearance: /
• Density: 1.17 g/cm³
• Vapor Pressure: 0.000142mmHg at 25°C
• Refractive Index: 1.569
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 2.73±0.10(Predicted)
• CAS DataBase Reference: 3-amino-4-methoxybenzonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 3-amino-4-methoxybenzonitrile(60979-25-1)
• EPA Substance Registry System: 3-amino-4-methoxybenzonitrile(60979-25-1)

Safety Data

• Hazardous Substances Data: 60979-25-1(Hazardous Substances Data)

Usage

General Description

3-Amino-4-methoxybenzonitrile is a chemical compound with the molecular formula C8H8N2O and a molecular weight of 148.16 g/mol. It is a white to light yellow crystalline solid that is insoluble in water. 3-Amino-4-methoxybenzonitrile is commonly used as a building block in the synthesis of pharmaceuticals and agrochemicals. Additionally, it is utilized as an intermediate in the production of dyes, pigments, and other organic compounds. 3-Amino-4-methoxybenzonitrile is considered to be potentially hazardous if ingested, inhaled, or dermally absorbed, and should be handled with proper safety precautions.

InChI:InChI=1/C8H8N2O/c1-11-8-3-2-6(5-9)4-7(8)10/h2-4H,10H2,1H3

Upstream product

• 939-80-0 4-chloro-3-nitrobenzonitrile 
• 124-41-4 sodium methylate 
• 33224-23-6 4-Cyano-2-nitroanisol 
• 874-90-8 4-methoxybenzonitrile 
• 31680-08-7 4-methoxy-3-nitrobenzaldehyde 

Downstream Products

• 1201666-79-6 3-azido-4-methoxybenzonitrile 
• 1377582-29-0 3-Isothiocyanato-4-methoxy-benzonitrile 
• 1377582-30-3 (5-cyano-2-methoxy-phenyl)-thiourea 
• 1110813-31-4 Dacomitinib 
• 17481-27-5 3-amino-4-methoxybenzamide 
• 1220628-02-3 6-((5-cyano-2-methoxyphenyl)amino)-8-((2,2,2-trifluoroethyl)amino)imidazo[1,2-b]pyridazine-3-carbonitrile 
• 857554-01-9 3-acetylamino-4-methoxy-benzonitrile 
• 65448-82-0 (5-cyano-2-methoxy-phenyl)-carbamic acid ethyl ester 

Relevant articles and documents

New diarylsulfonamide inhibitors of Leishmania infantum amastigotes

New drugs against visceral leishmaniasis with mechanisms of action differing from existing treatments and with adequate cost, stability, and properties are urgently needed. No antitubulin drug is currently in the clinic against Leishmania infantum, the causative agent of visceral leishmaniasis in the Mediterranean area. We have designed and synthesized a focused library of 350 compounds against the Leishmania tubulin based on the structure-activity relationship (SAR) and sequence differences between host and parasite. The compounds synthesized are accessible, stable, and appropriately soluble in water. We assayed the library against Leishmania promastigotes, axenic, and intracellular amastigotes and found 0, 8, and 16 active compounds, respectively, with a high success rate against intracellular amastigotes of over 10%, not including the cytotoxic compounds. Five compounds have a similar or better potency than the clinically used miltefosine. 14 compounds showed a host-dependent mechanism of action that might be advantageous as it may render them less susceptible to the development of drug resistance. The active compounds cluster in five chemical classes that provide structure-activity relationships for further hit improvement and facilitate series development. Molecular docking is consistent with the proposed mechanism of action, supported by the observed structure-activity relationships, and suggests a potential extension to other Leishmania species due to sequence similarities. A new family of diarylsulfonamides designed against the parasite tubulins is active against Leishmania infantum and represents a new class of potential drugs with favorable cost, stability, and aqueous solubility for the treatment of visceral leishmaniasis (VL). These results could be extended to other clinically relevant species of Leishmania spp.

Pyridyl Radical Cation for C?H Amination of Arenes

Electron-transfer photocatalysis provides access to the elusive and unprecedented N-pyridyl radical cation from selected N-substituted pyridinium reagents. The resulting C(sp2)?H functionalization of (hetero)arenes furnishes versatile intermediates for the development of valuable aminated aryl scaffolds. Mechanistic studies that include the first spectroscopic evidence of a spin-trapped N-pyridyl radical adduct implicate SET-triggered, pseudo-mesolytic cleavage of the N?X pyridinium reagents mediated by visible light.

PYRIDYL-THIAZOLYL INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION

This invention relates to thiazole I and its therapeutic and prophylactic uses, wherein the variables Rz, Q, J, R1, R3, R5, and R6 are defined in the specification. Disorders treated and/or prevented include rheumatoid arthritis.